



Montréal - The Ataxia Charlevoix Saguenay Foundation is pleased to announce the funding of six innovative research projects in 2023-2024. It is an investment of \$700,000 aimed to understand the underlying causes of ARSACS, develop effective treatments, and ultimately discover a cure.

“With a global network of expert researchers and a strong commitment to innovation, we work tirelessly to develop treatments, find a cure and enhance the quality of life for those living with ARSACS” said Jean Groleau, president and co-founder of the Ataxia Charlevoix- Saguenay Foundation.

The Foundation extends its gratitude to the researchers from around the world who submitted their proposals. The dedication demonstrated by these experts is a testament to the global community's commitment to combating ARSACS.

The Ataxia Charlevoix- Saguenay Foundation is a leading charitable organization dedicated to advancing research and supporting individuals affected by ARSACS. For further information about the Ataxia Charlevoix- Saguenay Foundation's ongoing activities, please visit its [website](#).

The awardees for 2023-2024 are:



Dr. Heather Durham & Dr. Benoit Gentil
McGill University, Montreal
“Therapeutics Approaches for ARSACS”



Dr. Alanna Watt & Dr Anne McKinney
McGill University, Montreal
*“Elucidating mechanisms underlying motor coordination rescue
in a mouse model of ARSACS”*



Dr. Francesca Maltecca
Universita Vita-Salute San Raffaele, Milan, Italy
*“A mouse-human single nuclei-RNA seq profiling in ARSACS cerebellum: understanding how
alterations in different cell types contribute to neurodegeneration”*



Dr. Simon Girard

Université du Québec à Chicoutimi

"Discovery of new ARSACS modifier genes in the Saguenay founder population"



Dr. Walid Houry

University of Toronto

"Structural Determination of Sacsin"



Dr. Stefan Strack
University of Iowa

"Exploring and treating cognitive dysmetria in the mouse model of ARSACS"

For inquiries, please contact: Sonia Gobeil at ataxia@arsacs.com